Following the merger of Apotex and Arrow, the combined Arrotex entity now has a considerable portfolio of respiratory medicines – including two new products
Arrotex Pharmaceuticals has announced a strategic partnership with Boehringer Ingelheim for the exclusive Australian reseller rights to respiratory products Spiriva (tiotropium 18 micrograms powder for inhalation) and Spiriva HandiHaler, both used for treatment of chronic obstructive pulmonary disease (COPD).
Following the 2019 merger of Apotex Australia and Arrow Pharmaceuticals, the combined Arrotex entity became Australia’s largest generic pharmaceutical and private label OTC business with around 50% market share of the country’s generic pharmacy market.
It now commands a significant portfolio of respiratory medicines, including GSK’s Seretide, Pavtide (Seretide authorised generic), Flixotide and Ventolin CFC Inhaler brands, along with AstraZeneca’s respiratory brands Symbicort Turbuhaler, Symbicort Rapihaler, Pulmicort, Omnaris, Alvesco, Bricanyl and Oxis.
Spiriva and Spiriva HandiHaler have now been added to this list.
In a recent statement, Arrotex said it is “committed to creating value for Australian community pharmacy”.
“Strategic partnerships such as this new Boehringer Ingelheim arrangement, as well as existing collaborations with GSK and AstraZeneca, represent a unique element of the Apotex and Arrow offer to pharmacy,” said Lisa Golden, Arrotex Chief Commercial Officer.
“Through our strategic partnerships, Arrotex creates value for Australian community pharmacy, by offering access to brand product discounts that would otherwise be unavailable to our customers.
“This is an example of Arrotex’ unique approach to value creation for our customers who are operating in the competitive retail pharmacy market.”
The partnership with Boehringer Ingelheim will take effect 10 February 2020 and Apotex and Arrow will soon contact pharmacies with details of commercial arrangements.